23:00:57 EST Wed 23 Jan 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:HALO from 2018-01-24 to 2019-01-23 - 43 items
DateSymPriceTypeHeadline
2019-01-09 13:30HALONews ReleaseHalozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
2018-12-27 07:25HALONews ReleaseFactors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth
2018-12-26 08:00HALONews ReleaseHalozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
2018-12-03 17:05HALONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO
2018-12-03 16:59HALONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO
2018-11-29 16:16HALONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO
2018-11-29 16:16HALONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO
2018-11-29 14:33HALONews ReleaseSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)
2018-11-26 16:05HALONews ReleaseHalozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival
2018-11-08 07:40HALONews ReleaseReport: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
2018-11-06 16:05HALONews ReleaseHalozyme Reports Third Quarter 2018 Financial Results
2018-11-06 08:00HALONews ReleaseHalozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications
2018-10-30 08:00HALONews ReleaseHalozyme Licenses New ENHANZE ® Targets For $25 Million Upfront Payment, Future Milestones And Royalties
2018-10-25 08:00HALONews ReleaseHalozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze ® Technology
2018-10-22 08:00HALONews ReleaseHalozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress
2018-10-17 09:00HALONews ReleaseMarket Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
2018-10-10 16:05HALONews ReleaseHalozyme To Host Third Quarter 2018 Financial Results Conference Call
2018-10-04 09:00HALONews ReleaseHalozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
2018-09-20 16:15HALONews ReleaseHalozyme Therapeutics To Participate In Upcoming Investor Conference
2018-09-17 08:00HALONews ReleaseHalozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin ®) In Canada
2018-09-10 08:00HALONews ReleaseHalozyme Appoints Bernadette Connaughton To Board Of Directors
2018-09-05 08:00HALONews ReleaseHalozyme Names Benjamin Hickey As Chief Commercial Officer
2018-08-23 10:30HALONews ReleaseRecent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
2018-08-22 08:30HALONews ReleaseHalozyme Therapeutics To Participate In Upcoming Investor Conferences
2018-08-07 16:21HALONews ReleaseHalozyme Reports Second Quarter 2018 Results
2018-08-07 15:46HALONews ReleaseHalozyme Therapeutics, Inc. to Host Earnings Call
2018-07-26 16:15HALONews ReleaseHalozyme Therapeutics To Participate In Upcoming Healthcare Conference
2018-07-26 08:00HALONews ReleasePhase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE ® Technology
2018-07-11 08:30HALONews ReleaseFDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
2018-07-06 08:00HALONews ReleaseHalozyme To Host Second Quarter 2018 Financial Results Conference Call
2018-06-13 08:00HALONews ReleaseReport: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
2018-06-11 08:30HALONews ReleaseHalozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
2018-06-01 08:30HALONews ReleaseHalozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer
2018-05-29 16:15HALONews ReleaseHalozyme Therapeutics To Participate In Upcoming Healthcare Conferences
2018-05-10 16:05HALONews ReleaseHalozyme Reports First Quarter 2018 Results
2018-04-10 08:00HALONews ReleaseHalozyme To Host First Quarter 2018 Financial Results Conference Call
2018-03-22 17:46HALONews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
2018-03-22 16:05HALONews ReleaseHalozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
2018-03-14 16:37HALONews ReleaseHalozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
2018-02-27 08:00HALONews ReleaseHalozyme Therapeutics To Present At Upcoming Healthcare Conference
2018-02-23 07:45HALONews ReleaseNew Research: Key Drivers of Growth for Trinseo S.A, Camden Property Trust, Lions Gate Entertainment, Aramark, J.M. Smucker, and Halozyme Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
2018-02-20 16:05HALONews ReleaseHalozyme Reports Fourth Quarter And Full-Year 2017 Results
2018-02-20 12:04HALONews ReleaseHalozyme Therapeutics, Inc. to Host Earnings Call